<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Rheumatoid factor: Biology and utility of measurement
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Rheumatoid factor: Biology and utility of measurement
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Rheumatoid factor: Biology and utility of measurement
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert H Shmerling, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Mark H Wener, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Philip Seo, MD, MHS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jul 19, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Rheumatoid factors (RFs) are antibodies directed against the Fc portion of immunoglobulin (Ig) G. The RF, as initially described by Waaler and Rose in 1940 and as commonly measured in clinical practice, is an IgM RF, although other Ig types, including IgG and IgA, can exhibit this characteristic.
        </p>
        <p>
         Testing for RF is primarily used for the diagnosis and establishing prognosis of rheumatoid arthritis (RA); however, RF may also be present in other rheumatic diseases and other conditions, including acute and chronic infections and neoplastic disease.
        </p>
        <p>
         The biology of RFs and the clinical utility of their measurement are reviewed here. Discussions of clinically useful biologic markers in RA, including RF, and of the diagnosis of RA are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/7503.html" rel="external">
          "Biologic markers in the assessment of rheumatoid arthritis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7504.html" rel="external">
          "Diagnosis and differential diagnosis of rheumatoid arthritis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          PATHOPHYSIOLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H2983264454">
         <span class="h2">
          Origins of rheumatoid factor
         </span>
         <span class="headingEndMark">
          —
         </span>
         The origin of rheumatoid factor (RF) is incompletely understood [
         <a href="#rid1">
          1,2
         </a>
         ]. An abnormal immune response appears to select, via antigenic stimulation, high-affinity RF from the host's natural antibody repertoire [
         <a href="#rid3">
          3
         </a>
         ]. This may occur in rheumatic diseases, such as rheumatoid arthritis (RA), and in a number of inflammatory disorders characterized by chronic antigen exposure, such as infective endocarditis (IE) and chronic hepatitis C virus infection. The development of RF after such infections has suggested that they represent an antibody response to antibodies that have reacted with microbes. This possibility is supported by experimental evidence showing that mice immunized with IgM-coated vesicular stomatitis virus (VSV) develop RFs [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         Normal human lymphoid tissue commonly possesses B lymphocytes with RF expression on the cell surface. However, RF is not routinely detectable in the circulation in the absence of an antigenic stimulus. Modified IgG, release of heavy chains from apoptotic B cells [
         <a href="#rid5">
          5
         </a>
         ], and components of microbial organisms (such as Epstein-Barr virus [
         <a href="#rid6">
          6
         </a>
         ]) may be triggers for RF production and could be important components of RA pathogenesis [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         Costimulation of B cells, perhaps initiated by chronic infection and mediated by toll-like receptors (TLRs), may allow B cells with low-affinity receptors for IgG to become activated. TLRs are components of the innate immune system and provide signals after engaging various bacterial and viral products [
         <a href="#rid7">
          7,8
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3985.html" rel="external">
          "Toll-like receptors: Roles in disease and therapy"
         </a>
         .)
        </p>
        <p>
         RFs possess significant heterogeneity related to mutations within heavy and light chain genes [
         <a href="#rid9">
          9
         </a>
         ]. While IgM RFs from patients with RA react with a variety of antigenic sites on autologous IgG [
         <a href="#rid10">
          10
         </a>
         ], certain binding specificities appear to be more closely associated with seropositive RA than other specificities [
         <a href="#rid11">
          11
         </a>
         ]. These include specificity for IgG1, IgG2, and IgG4 more than IgG3, and to the Fc elbow and tail regions more than the Fc receptor binding region.
        </p>
        <p>
         RFs may also react against a variety of cellular and tissue antigens but may have different biologic activity in different hosts and anatomic locations. As an example, one report of RF derived from synovial tissue lymphocytes in a patient with RA found specificity for gastric glands, nuclei, and smooth muscle; by contrast, RF derived from a control patient's peripheral blood did not show this pattern of reactivity [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Possible functions
         </span>
         <span class="headingEndMark">
          —
         </span>
         The function of RF is poorly understood. Possible functions include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Binding and processing of antigens embedded in immune complexes
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Presentation of antigens to T lymphocytes in the presence of human leukocyte antigen (HLA) molecules
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Immune tolerance
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Amplification of the humoral response to bacterial or parasitic infection
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Immune complex clearance
        </p>
        <p>
        </p>
        <p>
         The role of RFs in the pathogenesis and perpetuation of RA or other rheumatic diseases is also unknown. One model of RA pathogenesis places RF in a key etiopathogenic role as an antibody to immune complexes that activates the complement cascade and promotes production of inflammatory mediators, thereby facilitating a state of ongoing inflammation [
         <a href="#rid6">
          6
         </a>
         ]. There is in vitro evidence that RF may promote inflammatory cytokine production through interactions with anti-citrullinated peptide antibodies (ACPA) immune complexes in patients with RA [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
         While genetic factors appear to be important in the development of RA, the interplay between genetic predisposition, autoantibody production, and disease development is complex and incompletely understood. A number of studies have identified genetic differences between individuals with RF-negative and RF-positive RA [
         <a href="#rid14">
          14-17
         </a>
         ]. In addition, a high correlation for RF has been noted among identical twins with RA [
         <a href="#rid18">
          18
         </a>
         ]. However, other studies have demonstrated that patients with RF-negative and RF-positive RA may have similar HLA susceptibility alleles [
         <a href="#rid19">
          19-21
         </a>
         ], including the shared epitope, suggesting that there may be a similar immunogenetic predisposition to RA in some patients that is independent of RF. (See
         <a class="medical medical_review" href="/z/d/html/7487.html" rel="external">
          "HLA and other susceptibility genes in rheumatoid arthritis", section on 'Seronegative rheumatoid arthritis'
         </a>
         .)
        </p>
        <p>
         The pathogenesis of RA is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7513.html" rel="external">
          "Pathogenesis of rheumatoid arthritis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          CLINICAL DISORDERS ASSOCIATED WITH RHEUMATOID FACTOR POSITIVITY
         </span>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Rheumatic disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients may have detectable serum rheumatoid factor (RF) in a variety of rheumatic disorders, many of which share similar features, such as symmetric polyarthritis and constitutional symptoms [
         <a href="#rid22">
          22
         </a>
         ]. A positive RF test can also be found in nonrheumatic disorders and in healthy subjects [
         <a href="#rid22">
          22
         </a>
         ]. The rheumatic disorders associated with a positive RF include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rheumatoid arthritis (RA) – 26 to 90 percent (see
         <a class="local">
          'Clinical uses of rheumatoid factor testing'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sjögren's disease – 75 to 95 percent (see
         <a class="medical medical_review" href="/z/d/html/5603.html" rel="external">
          "Diagnosis and classification of Sjögren’s disease"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mixed connective tissue disease – 50 to 60 percent (see
         <a class="medical medical_review" href="/z/d/html/7546.html" rel="external">
          "Mixed connective tissue disease"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mixed cryoglobulinemia (types II and III) – 40 to 100 percent (see
         <a class="medical medical_review" href="/z/d/html/3062.html" rel="external">
          "Mixed cryoglobulinemia syndrome: Clinical manifestations and diagnosis"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Systemic lupus erythematosus – 15 to 35 percent (see
         <a class="medical medical_review" href="/z/d/html/4668.html" rel="external">
          "Clinical manifestations and diagnosis of systemic lupus erythematosus in adults"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Polymyositis or dermatomyositis – 5 to 10 percent (see
         <a class="medical medical_review" href="/z/d/html/5159.html" rel="external">
          "Clinical manifestations of dermatomyositis and polymyositis in adults"
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         The reported sensitivity of the RF test in RA has been as high as 90 percent. However, population-based studies, which include patients with mild disease, have found much lower rates of RF-positive RA (26 to 60 percent) [
         <a href="#rid23">
          23-26
         </a>
         ]. This difference may reflect classification criteria that led published series of patients with RA to be biased toward more severe (and more seropositive) disease, thereby overestimating the sensitivity of RF in RA. A 2022 review found that the sensitivity of RF for RA was higher for males than females [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
         Other autoantibodies, including anti-citrullinated peptide antibodies (ACPA, which include anti-cyclic citrullinated peptides [anti-CCP]), may be present in patients with suspected or established RA who are RF negative, as well as those who are positive for RF [
         <a href="#rid28">
          28
         </a>
         ]. The optimal clinical use of ACPA testing and its relationship to RF testing remain uncertain [
         <a href="#rid29">
          29-33
         </a>
         ]. Although ACPA and RF have similar sensitivity for the diagnosis of RA, ACPA is a more specific marker for RA [
         <a href="#rid34">
          34
         </a>
         ]. Of note, the 2010 revised classification criteria for RA include both RF and ACPA [
         <a href="#rid35">
          35
         </a>
         ]. ACPA testing is discussed in more detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7503.html" rel="external">
          "Biologic markers in the assessment of rheumatoid arthritis", section on 'Anti-citrullinated peptide antibodies'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7504.html" rel="external">
          "Diagnosis and differential diagnosis of rheumatoid arthritis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
         IgG and IgA RFs are occasionally present in patients with RA in the absence of IgM RF [
         <a href="#rid36">
          36,37
         </a>
         ]. Measurement of these non-IgM RFs is not widely available in the United States. However, they may be of prognostic value since there is evidence suggesting that IgG, IgA, and 7S IgM RFs are associated with more severe disease [
         <a href="#rid38">
          38-42
         </a>
         ]. This risk appears to be independent of human leukocyte antigen (HLA) alleles associated with severe disease [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Nonrheumatic disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nonrheumatic disorders characterized by chronic antigenic stimulation (especially with circulating immune complexes or polyclonal B lymphocyte activation) commonly induce RF production  (
         <a class="graphic graphic_table graphicRef74945" href="/z/d/graphic/74945.html" rel="external">
          table 1
         </a>
         ). Included in this group are [
         <a href="#rid22">
          22
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Indolent or chronic infection, as with infective endocarditis (IE) or with hepatitis B or C virus infection. As an example, studies have demonstrated that hepatitis C virus infection is associated with a positive RF in 54 to 76 percent of cases [
         <a href="#rid43">
          43-46
         </a>
         ] and is even more common in patients with hepatitis C virus and mixed cryoglobulinemia. RF production typically ceases with resolution of the infection in these disorders. These molecules may be produced by activated hepatic lymphocytes [
         <a href="#rid47">
          47
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3062.html" rel="external">
          "Mixed cryoglobulinemia syndrome: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inflammatory or fibrosing pulmonary disorders, such as sarcoidosis [
         <a href="#rid48">
          48-50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Malignancy, particularly B-cell neoplasms [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Primary biliary cholangitis (previously referred to as primary biliary cirrhosis).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Healthy individuals
         </span>
         <span class="headingEndMark">
          —
         </span>
         RFs have been found in up to 4 percent of young, healthy individuals [
         <a href="#rid52">
          52
         </a>
         ]. The reported incidence may be higher in older subjects without rheumatic disease, ranging from 3 to 25 percent [
         <a href="#rid53">
          53,54
         </a>
         ]. Part of this wide range may be explained by a higher incidence of RF among chronically ill older adults as compared with healthy older patients [
         <a href="#rid55">
          55
         </a>
         ]. However, other studies have reported that the prevalence of RF among healthy older individuals is low and does not increase with aging [
         <a href="#rid56">
          56,57
         </a>
         ]. In a large representative population study in the United States, RF was present in 5 percent of the older population [
         <a href="#rid58">
          58
         </a>
         ]. When present, RF is typically found in low to moderate amounts (eg, titers of 1:40 to 1:160) in individuals with no demonstrable rheumatic or inflammatory disease.
        </p>
        <p>
         Cigarette smoking is associated with the presence of RF [
         <a href="#rid59">
          59,60
         </a>
         ] as well as seropositive RA; whether this association is causal remains uncertain. (See
         <a class="medical medical_review" href="/z/d/html/7519.html" rel="external">
          "Epidemiology of, risk factors for, and possible causes of rheumatoid arthritis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          CLINICAL USES OF RHEUMATOID FACTOR TESTING
         </span>
        </p>
        <p class="headingAnchor" id="H2989732150">
         <span class="h2">
          Rheumatoid factor is not useful as a screening test
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although rheumatoid factor (RF) may be found in the circulation prior to the development of rheumatoid arthritis (RA), most asymptomatic persons with a positive RF do not progress to RA; as a result, measurement of RF is a poor screening test [
         <a href="#rid56">
          56
         </a>
         ]. Population-based studies have shown that some healthy people with a positive RF develop RA over time, especially if more than one isotype is persistently elevated and if there are high levels of RF [
         <a href="#rid56">
          56,61
         </a>
         ]. Retrospective study of stored blood samples collected as part of routine blood donation has demonstrated that nearly 30 percent of those who later develop RA have serum RF present for a year or more prior to diagnosis (median 4.5 years) [
         <a href="#rid62">
          62,63
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Diagnostic value
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnostic use of RF testing is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7504.html" rel="external">
          "Diagnosis and differential diagnosis of rheumatoid arthritis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Rheumatoid factor quantification
         </span>
         <span class="headingEndMark">
          —
         </span>
         The quantified level of RF should be considered when analyzing its utility. The higher the amount, the greater the likelihood that the patient has a rheumatic disease. There are, however, frequent exceptions to this rule, particularly among patients with one of the chronic inflammatory disorders noted above. Furthermore, the use of a higher cutoff for diagnosis decreases the sensitivity of the test as it simultaneously increases the specificity (by decreasing the incidence of false-positive results). In a study by the author and colleagues, for example, an RF titer of 1:40 or greater was 28 percent sensitive and 87 percent specific for RA; by comparison, a titer of 1:640 or greater increased the specificity to 99 percent (ie, almost no false-positive results) but reduced the sensitivity to 8 percent [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p>
         Treatment for RA can lower the level of RF [
         <a href="#rid65">
          65
         </a>
         ], but such fluctuations do not reliably reflect disease activity.
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Prognostic value
         </span>
         <span class="headingEndMark">
          —
         </span>
         The presence of RF may predict a worse prognosis and the degree of responsiveness to particular drugs. RF-positive patients with RA may experience more aggressive and erosive joint disease and extraarticular manifestations than those who are RF negative [
         <a href="#rid66">
          66-70
         </a>
         ]. Similar findings have been observed in JIA [
         <a href="#rid71">
          71
         </a>
         ]. These general observations, however, are of limited utility in an individual patient because of wide interpatient variability. In addition, the effect of RF status on radiographic progression may be decreasing in the era of earlier and more effective therapy [
         <a href="#rid72">
          72
         </a>
         ]. Accurate prediction of the disease course is not possible from the RF alone. (See
         <a class="medical medical_review" href="/z/d/html/7487.html" rel="external">
          "HLA and other susceptibility genes in rheumatoid arthritis"
         </a>
         .)
        </p>
        <p>
         RF status may be useful in combination with other indicators, including ACPA status, C-reactive protein and erythrocyte sedimentation rate levels, and severity of synovitis on physical exam, to predict progression of radiographic changes in patients with RA and to guide treatment [
         <a href="#rid73">
          73-75
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7516.html" rel="external">
          "General principles and overview of management of rheumatoid arthritis in adults", section on 'Prognosis'
         </a>
         .)
        </p>
        <p>
         RF status may have value in predicting response to treatment and comorbidity. As an example, the anti-CD20 B-cell depleting monoclonal antibody,
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , may be less effective for patients with seronegative RA than for those with seropositive RA [
         <a href="#rid76">
          76
         </a>
         ]. Conversely, anti-tumor necrosis factor (TNF) therapy may be less effective in RF-positive RA than in seronegative disease [
         <a href="#rid77">
          77
         </a>
         ]. In addition, the presence of RF among patients with RA may be associated with a higher risk of cardiovascular disease [
         <a href="#rid78">
          78
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2374481">
         <span class="h2">
          Analytical considerations
         </span>
         <span class="headingEndMark">
          —
         </span>
         The presence of RF can be detected by a variety of techniques. These include agglutination of IgG-sensitized sheep red cells or of bentonite or latex particles coated with human IgG, with results typically reported as titers based on manual dilution of the serum tested. Assays performed by immunoturbidimetry and nephelometry (two methods that measure light scatter caused by antigen-antibody interactions and widely used in large clinical laboratories) and enzyme-linked immunosorbent assay (ELISA) are usually quantified in terms of international units per mL; these are typically better standardized than manual methods [
         <a href="#rid79">
          79-84
         </a>
         ]. Unfortunately, measurement of RF is imperfectly standardized; therefore, the same patient may have different results in different laboratories. Although no one technique has a clear advantage over others, automated methods, such as nephelometry, immunoturbidimetry, and ELISA, tend to be more reproducible than manual methods.
        </p>
        <p>
         RFs in patient specimens sometimes interfere with measurements of other plasma components, including IgM antibodies to infectious agents. For example, IgM RFs can cause false-positive results in point-of-care tests for IgM antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent of coronavirus disease 2019 (COVID-19) [
         <a href="#rid85">
          85
         </a>
         ], or in assays for inflammatory cytokines [
         <a href="#rid86">
          86
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Cost
         </span>
         <span class="headingEndMark">
          —
         </span>
         Measurement of the RF titer is generally inexpensive. However, the cost per true-positive result may be high if the test is ordered in patients with a low prevalence of disease. In a 1992 analysis of 563 patients studied over a six-month period, for example, the cost per true-positive RF result was USD $563 [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathophysiology
         </strong>
         – Rheumatoid factors (RFs) are antibodies directed against the Fc portion of IgG. Normal human lymphoid tissue commonly possesses B lymphocytes with RF expression on the cell surface. However, RF is not routinely detectable in the circulation in the absence of an antigenic stimulus. How chronic infections and rheumatic diseases lead to increased RF in serum is uncertain. (See
         <a class="local">
          'Pathophysiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Possible physiologic function
         </strong>
         – Whether RF has a physiologic function is uncertain, though some potentially pathogenic and other potentially beneficial activities have been suggested. (See
         <a class="local">
          'Possible functions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Disorders associated with RF positivity
         </strong>
         – RF is detected in the setting of various rheumatic diseases, in infections, in other inflammatory diseases, and in some healthy people. (See
         <a class="local">
          'Clinical disorders associated with rheumatoid factor positivity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Role in the diagnosis of rheumatoid arthritis
         </strong>
         – The role of RF testing in the diagnosis of rheumatoid arthritis (RA) is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7504.html" rel="external">
          "Diagnosis and differential diagnosis of rheumatoid arthritis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          No role as a screening test
         </strong>
         – Measurement of RF has little value as a screening test to diagnose or exclude rheumatic disease in either healthy populations or in those with arthralgias. (See
         <a class="local">
          'Clinical uses of rheumatoid factor testing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Role in prognosis - Although, in aggregate, seropositive disease and higher titers of RF are associated with more severe RA, measurement of RF has limited prognostic value in the individual patient with RA. When RF is combined with other clinical data (such as joint count, anti-citrullinated peptide antibodies [ACPA] results, and C-reactive protein measurement), prediction can be improved but is still limited. (See
         <a class="local">
          'Prognostic value'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Sutton B, Corper A, Bonagura V, Taussig M. The structure and origin of rheumatoid factors. Immunol Today 2000; 21:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Falkenburg WJJ, von Richthofen HJ, Rispens T. On the origin of rheumatoid factors: Insights from analyses of variable region sequences. Semin Arthritis Rheum 2019; 48:603.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carayannopoulos MO, Potter KN, Li Y, et al. Evidence that human immunoglobulin M rheumatoid factors can Be derived from the natural autoantibody pool and undergo an antigen driven immune response in which somatically mutated rheumatoid factors have lower affinities for immunoglobulin G Fc than their germline counterparts. Scand J Immunol 2000; 51:327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fehr T, Bachmann MF, Bucher E, et al. Role of repetitive antigen patterns for induction of antibodies against antibodies. J Exp Med 1997; 185:1785.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maibom-Thomsen SL, Trier NH, Holm BE, et al. Immunoglobulin G structure and rheumatoid factor epitopes. PLoS One 2019; 14:e0217624.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan EM, Smolen JS. Historical observations contributing insights on etiopathogenesis of rheumatoid arthritis and role of rheumatoid factor. J Exp Med 2016; 213:1937.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shlomchik MJ, Zharhary D, Saunders T, et al. A rheumatoid factor transgenic mouse model of autoantibody regulation. Int Immunol 1993; 5:1329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rifkin IR, Leadbetter EA, Busconi L, et al. Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev 2005; 204:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Youngblood K, Fruchter L, Ding G, et al. Rheumatoid factors from the peripheral blood of two patients with rheumatoid arthritis are genetically heterogeneous and somatically mutated. J Clin Invest 1994; 93:852.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duquerroy S, Stura EA, Bressanelli S, et al. Crystal structure of a human autoimmune complex between IgM rheumatoid factor RF61 and IgG1 Fc reveals a novel epitope and evidence for affinity maturation. J Mol Biol 2007; 368:1321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Falkenburg WJJ, Oskam N, Koers J, et al. Identification of Clinically and Pathophysiologically Relevant Rheumatoid Factor Epitopes by Engineered IgG Targets. Arthritis Rheumatol 2020; 72:2005.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thorpe SJ, Børretzen M, Bailey SW, et al. Human monoclonal rheumatoid factors: incidence of cross-reactions with tissue components and correlation with VH gene usage. Immunology 1994; 83:114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sokolove J, Johnson DS, Lahey LJ, et al. Rheumatoid factor as a potentiator of anti-citrullinated protein antibody-mediated inflammation in rheumatoid arthritis. Arthritis Rheumatol 2014; 66:813.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fries JF, Wolfe F, Apple R, et al. HLA-DRB1 genotype associations in 793 white patients from a rheumatoid arthritis inception cohort: frequency, severity, and treatment bias. Arthritis Rheum 2002; 46:2320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Terao C, Ohmura K, Ikari K, et al. ACPA-negative RA consists of two genetically distinct subsets based on RF positivity in Japanese. PLoS One 2012; 7:e40067.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mackie SL, Taylor JC, Martin SG, et al. A spectrum of susceptibility to rheumatoid arthritis within HLA-DRB1: stratification by autoantibody status in a large UK population. Genes Immun 2012; 13:120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balsa A, Cabezón A, Orozco G, et al. Influence of HLA DRB1 alleles in the susceptibility of rheumatoid arthritis and the regulation of antibodies against citrullinated proteins and rheumatoid factor. Arthritis Res Ther 2010; 12:R62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacGregor AJ, Bamber S, Carthy D, et al. Heterogeneity of disease phenotype in monozygotic twins concordant for rheumatoid arthritis. Br J Rheumatol 1995; 34:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vehe RK, Nepom GT, Wilske KR, et al. Erosive rheumatoid factor negative and positive rheumatoid arthritis are immunogenetically similar. J Rheumatol 1994; 21:194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           al-Jarallah KF, Buchanan WW, Sastry A, Singal DP. Seronegative rheumatoid arthritis and HLA-DR4. J Rheumatol 1994; 21:190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mattey DL, Hassell AB, Dawes PT, et al. Independent association of rheumatoid factor and the HLA-DRB1 shared epitope with radiographic outcome in rheumatoid arthritis. Arthritis Rheum 2001; 44:1529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shmerling RH, Delbanco TL. The rheumatoid factor: an analysis of clinical utility. Am J Med 1991; 91:528.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lichtenstein MJ, Pincus T. Rheumatoid arthritis identified in population based cross sectional studies: low prevalence of rheumatoid factor. J Rheumatol 1991; 18:989.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mikkelsen WM, Dodge HJ, Duff IF, Kato H. Estimates of the prevalence of rheumatic diseases in the population of Tecumseh, Michigan, 1959-60. J Chronic Dis 1967; 20:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cathcart ES, O'Sullivan JB. Rheumatoid arthritis in a New England town. A prevalence study in Sudbury, Massachusetts. N Engl J Med 1970; 282:421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kellgren JH. Epidemiology of rheumatoid arthritis. Arthritis Rheum 1966; 9:658.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hadwen B, Yu R, Cairns E, Barra L. Presence of Autoantibodies in Males and Females With Rheumatoid Arthritis: A Systematic Review and Metaanalysis. J Rheumatol 2022; 49:663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee DM, Schur PH. Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis 2003; 62:870.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vander Cruyssen B, Peene I, Cantaert T, et al. Anti-citrullinated protein/peptide antibodies (ACPA) in rheumatoid arthritis: specificity and relation with rheumatoid factor. Autoimmun Rev 2005; 4:468.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shmerling RH. Testing for anti-cyclic citrullinated peptide antibodies: is it time to set this genie free? Arch Intern Med 2009; 169:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hodkinson B, Meyer PW, Musenge E, et al. The diagnostic utility of the anti-CCP antibody test is no better than rheumatoid factor in South Africans with early rheumatoid arthritis. Clin Rheumatol 2010; 29:615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peoples C, Valiyil R, Davis RB, Shmerling RH. Clinical use of anti-cyclic citrullinated peptide antibody testing. J Clin Rheumatol 2013; 19:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang PY, Yang CT, Cheng CH, Yu KH. Diagnostic performance of anti-cyclic citrullinated peptide and rheumatoid factor in patients with rheumatoid arthritis. Int J Rheum Dis 2016; 19:880.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aggarwal R, Liao K, Nair R, et al. Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis. Arthritis Rheum 2009; 61:1472.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62:2569.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gioud-Paquet M, Auvinet M, Raffin T, et al. IgM rheumatoid factor (RF), IgA RF, IgE RF, and IgG RF detected by ELISA in rheumatoid arthritis. Ann Rheum Dis 1987; 46:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonagura VR, Wedgwood JF, Agostino N, et al. Seronegative rheumatoid arthritis, rheumatoid factor cross reactive idiotype expression, and hidden rheumatoid factors. Ann Rheum Dis 1989; 48:488.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Leeuwen MA, Westra J, van Riel PL, et al. IgM, IgA, and IgG rheumatoid factors in early rheumatoid arthritis predictive of radiological progression? Scand J Rheumatol 1995; 24:146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coughlan RJ, Gordon Y, Clark B, Panayi GS. 7S IgM in the sera of patients with arthritis. Br J Rheumatol 1987; 26:108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Zeben D, Hazes JM, Zwinderman AH, et al. Clinical significance of rheumatoid factors in early rheumatoid arthritis: results of a follow up study. Ann Rheum Dis 1992; 51:1029.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eberhardt KB, Truedsson L, Pettersson H, et al. Disease activity and joint damage progression in early rheumatoid arthritis: relation to IgG, IgA, and IgM rheumatoid factor. Ann Rheum Dis 1990; 49:906.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cabral D, Katz JN, Weinblatt ME, et al. Development and assessment of indicators of rheumatoid arthritis severity: results of a Delphi panel. Arthritis Rheum 2005; 53:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pawlotsky JM, Roudot-Thoraval F, Simmonds P, et al. Extrahepatic immunologic manifestations in chronic hepatitis C and hepatitis C virus serotypes. Ann Intern Med 1995; 122:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clifford BD, Donahue D, Smith L, et al. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology 1995; 21:613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pawlotsky JM, Ben Yahia M, Andre C, et al. Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology 1994; 19:841.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lienesch D, Morris R, Metzger A, et al. Absence of cyclic citrullinated peptide antibody in nonarthritic patients with chronic hepatitis C infection. J Rheumatol 2005; 32:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sansonno D, De Vita S, Iacobelli AR, et al. Clonal analysis of intrahepatic B cells from HCV-infected patients with and without mixed cryoglobulinemia. J Immunol 1998; 160:3594.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oreskes I, Siltzbach LE. Changes in rheumatoid factor activity during the course of sarcoidosis. Am J Med 1968; 44:60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kobak S, Sever F, Sivrikoz ON, Orman M. Sarcoidois: is it only a mimicker of primary rheumatic disease? A single center experience. Ther Adv Musculoskelet Dis 2014; 6:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thelier N, Assous N, Job-Deslandre C, et al. Osteoarticular involvement in a series of 100 patients with sarcoidosis referred to rheumatology departments. J Rheumatol 2008; 35:1622.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brickmann K, Brezinschek RI, Yazdani-Biuki B, et al. Superior specificity of anti-citrullinated peptide antibodies in patients with chronic lymphocytic leukemia and arthritis. Clin Exp Rheumatol 2010; 28:888.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newkirk MM. Rheumatoid factors: what do they tell us? J Rheumatol 2002; 29:2034.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cammarata RJ, Rodnan GP, Fennell RH. Serum anti-gamma-globulin and antinuclear factors in the aged. JAMA 1967; 199:455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LITWIN SD, SINGER JM. STUDIES OF THE INCIDENCE AND SIGNIFICANCE OF ANTI-GAMMA GLOBULIN FACTORS IN THE AGING. Arthritis Rheum 1965; 8:538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Juby AG, Davis P, McElhaney JE, Gravenstein S. Prevalence of selected autoantibodies in different elderly subpopulations. Br J Rheumatol 1994; 33:1121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nielsen SF, Bojesen SE, Schnohr P, Nordestgaard BG. Elevated rheumatoid factor and long term risk of rheumatoid arthritis: a prospective cohort study. BMJ 2012; 345:e5244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolfe F, Cathey MA, Roberts FK. The latex test revisited. Rheumatoid factor testing in 8,287 rheumatic disease patients. Arthritis Rheum 1991; 34:951.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hsu FC, Starkebaum G, Boyko EJ, Dominitz JA. Prevalence of rheumatoid arthritis and hepatitis C in those age 60 and older in a US population based study. J Rheumatol 2003; 30:455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newkirk MM, Mitchell S, Procino M, et al. Chronic smoke exposure induces rheumatoid factor and anti-heat shock protein 70 autoantibodies in susceptible mice and humans with lung disease. Eur J Immunol 2012; 42:1051.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ishikawa Y, Ikari K, Hashimoto M, et al. Shared epitope defines distinct associations of cigarette smoking with levels of anticitrullinated protein antibody and rheumatoid factor. Ann Rheum Dis 2019; 78:1480.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Halldórsdóttir HD, Jónsson T, Thorsteinsson J, Valdimarsson H. A prospective study on the incidence of rheumatoid arthritis among people with persistent increase of rheumatoid factor. Ann Rheum Dis 2000; 59:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nielen MM, van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004; 50:380.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tracy A, Buckley CD, Raza K. Pre-symptomatic autoimmunity in rheumatoid arthritis: when does the disease start? Semin Immunopathol 2017; 39:423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shmerling RH, Delbanco TL. How useful is the rheumatoid factor? An analysis of sensitivity, specificity, and predictive value. Arch Intern Med 1992; 152:2417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Moel EC, Derksen VFAM, Trouw LA, et al. In rheumatoid arthritis, changes in autoantibody levels reflect intensity of immunosuppression, not subsequent treatment response. Arthritis Res Ther 2019; 21:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scott DL, Smith C, Kingsley G. Joint damage and disability in rheumatoid arthritis: an updated systematic review. Clin Exp Rheumatol 2003; 21:S20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carpenter L, Nikiphorou E, Sharpe R, et al. Have radiographic progression rates in early rheumatoid arthritis changed? A systematic review and meta-analysis of long-term cohorts. Rheumatology (Oxford) 2016; 55:1053.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aletaha D, Alasti F, Smolen JS. Rheumatoid factor determines structural progression of rheumatoid arthritis dependent and independent of disease activity. Ann Rheum Dis 2013; 72:875.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang S, He X, Doyle TJ, et al. Association of rheumatoid arthritis-related autoantibodies with pulmonary function test abnormalities in a rheumatoid arthritis registry. Clin Rheumatol 2019; 38:3401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Terao C, Yamakawa N, Yano K, et al. Rheumatoid Factor Is Associated With the Distribution of Hand Joint Destruction in Rheumatoid Arthritis. Arthritis Rheumatol 2015; 67:3113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aggarwal A, Dabadghao S, Naik S, Misra R. Serum IgM rheumatoid factor by enzyme-linked immunosorbent assay (ELISA) delineates a subset of patients with deforming joint disease in seronegative juvenile rheumatoid arthritis. Rheumatol Int 1994; 14:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carpenter L, Norton S, Nikiphorou E, et al. Reductions in Radiographic Progression in Early Rheumatoid Arthritis Over Twenty-Five Years: Changing Contribution From Rheumatoid Factor in Two Multicenter UK Inception Cohorts. Arthritis Care Res (Hoboken) 2017; 69:1809.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Visser K, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al. A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study. Ann Rheum Dis 2010; 69:1333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vastesaeger N, Xu S, Aletaha D, et al. A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology (Oxford) 2009; 48:1114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takeuchi T, Soen S, Ishiguro N, et al. Predictors of new bone erosion in rheumatoid arthritis patients receiving conventional synthetic disease-modifying antirheumatic drugs: Analysis of data from the DRIVE and DESIRABLE studies. Mod Rheumatol 2021; 31:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Edwards JC, Cambridge G. Prospects for B-cell-targeted therapy in autoimmune disease. Rheumatology (Oxford) 2005; 44:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takeuchi T, Miyasaka N, Inui T, et al. High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the RISING study. Arthritis Res Ther 2017; 19:194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berendsen MLT, van Maaren MC, Arts EEA, et al. Anticyclic Citrullinated Peptide Antibodies and Rheumatoid Factor as Risk Factors for 10-year Cardiovascular Morbidity in Patients with Rheumatoid Arthritis: A Large Inception Cohort Study. J Rheumatol 2017; 44:1325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Waaler E. On the occurrence of a factor in human serum activating the specific agglutination of sheep blood corpuscles. Acta Path Microbiol Scand 1940; 17:172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           PLOTZ CM, SINGER JM. The latex fixation test. I. Application to the serologic diagnosis of rheumatoid arthritis. Am J Med 1956; 21:888.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roberts-Thomson PJ, McEvoy R, Langhans T, Bradley J. Routine quantification of rheumatoid factor by rate nephelometry. Ann Rheum Dis 1985; 44:379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Larkin JG, Sturrock RD, Stimson WH. A rapid enzyme immunoassay for the detection of IgM rheumatoid factor--a comparison of "sero-negative" and "sero-positive" rheumatoid patients. J Clin Lab Immunol 1986; 20:207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keshgegian AA, Straub CW, Loos EF, Grenoble BK. Rheumatoid factor measured with the QM300 nephelometer: clinical sensitivity and specificity. Clin Chem 1994; 40:943.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolfe F. A comparison of IgM rheumatoid factor by nephelometry and latex methods: clinical and laboratory significance. Arthritis Care Res 1998; 11:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang Q, Du Q, Guo B, et al. A Method To Prevent SARS-CoV-2 IgM False Positives in Gold Immunochromatography and Enzyme-Linked Immunosorbent Assays. J Clin Microbiol 2020; 58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Todd DJ, Knowlton N, Amato M, et al. Erroneous augmentation of multiplex assay measurements in patients with rheumatoid arthritis due to heterophilic binding by serum rheumatoid factor. Arthritis Rheum 2011; 63:894.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1824 Version 28.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10740238" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : The structure and origin of rheumatoid factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30032973" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : On the origin of rheumatoid factors: Insights from analyses of variable region sequences.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10736104" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Evidence that human immunoglobulin M rheumatoid factors can Be derived from the natural autoantibody pool and undergo an antigen driven immune response in which somatically mutated rheumatoid factors have lower affinities for immunoglobulin G Fc than their germline counterparts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9151704" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Role of repetitive antigen patterns for induction of antibodies against antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31199818" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Immunoglobulin G structure and rheumatoid factor epitopes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27621417" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Historical observations contributing insights on etiopathogenesis of rheumatoid arthritis and role of rheumatoid factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8268138" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : A rheumatoid factor transgenic mouse model of autoantibody regulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15790348" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Toll-like receptors, endogenous ligands, and systemic autoimmune disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7509350" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Rheumatoid factors from the peripheral blood of two patients with rheumatoid arthritis are genetically heterogeneous and somatically mutated.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17395205" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Crystal structure of a human autoimmune complex between IgM rheumatoid factor RF61 and IgG1 Fc reveals a novel epitope and evidence for affinity maturation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32648642" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Identification of Clinically and Pathophysiologically Relevant Rheumatoid Factor Epitopes by Engineered IgG Targets.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7821955" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Human monoclonal rheumatoid factors: incidence of cross-reactions with tissue components and correlation with VH gene usage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24757134" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Rheumatoid factor as a potentiator of anti-citrullinated protein antibody-mediated inflammation in rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12355479" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : HLA-DRB1 genotype associations in 793 white patients from a rheumatoid arthritis inception cohort: frequency, severity, and treatment bias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22792215" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : ACPA-negative RA consists of two genetically distinct subsets based on RF positivity in Japanese.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21881596" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : A spectrum of susceptibility to rheumatoid arthritis within HLA-DRB1: stratification by autoantibody status in a large UK population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20370905" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Influence of HLA DRB1 alleles in the susceptibility of rheumatoid arthritis and the regulation of antibodies against citrullinated proteins and rheumatoid factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7728394" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Heterogeneity of disease phenotype in monozygotic twins concordant for rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8182623" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Erosive rheumatoid factor negative and positive rheumatoid arthritis are immunogenetically similar.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8182622" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Seronegative rheumatoid arthritis and HLA-DR4.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11465703" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Independent association of rheumatoid factor and the HLA-DRB1 shared epitope with radiographic outcome in rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1951415" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : The rheumatoid factor: an analysis of clinical utility.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1920334" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Rheumatoid arthritis identified in population based cross sectional studies: low prevalence of rheumatoid factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5298089" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Estimates of the prevalence of rheumatic diseases in the population of Tecumseh, Michigan, 1959-60.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5412189" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Rheumatoid arthritis in a New England town. A prevalence study in Sudbury, Massachusetts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5332842" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Epidemiology of rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35293336" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Presence of Autoantibodies in Males and Females With Rheumatoid Arthritis: A Systematic Review and Metaanalysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12922961" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Clinical utility of the anti-CCP assay in patients with rheumatic diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16137613" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Anti-citrullinated protein/peptide antibodies (ACPA) in rheumatoid arthritis: specificity and relation with rheumatoid factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19139318" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Testing for anti-cyclic citrullinated peptide antibodies: is it time to set this genie free?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20127131" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : The diagnostic utility of the anti-CCP antibody test is no better than rheumatoid factor in South Africans with early rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23965485" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Clinical use of anti-cyclic citrullinated peptide antibody testing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25940989" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Diagnostic performance of anti-cyclic citrullinated peptide and rheumatoid factor in patients with rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19877103" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20872595" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3813676" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : IgM rheumatoid factor (RF), IgA RF, IgE RF, and IgG RF detected by ELISA in rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2662917" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Seronegative rheumatoid arthritis, rheumatoid factor cross reactive idiotype expression, and hidden rheumatoid factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7777825" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : IgM, IgA, and IgG rheumatoid factors in early rheumatoid arthritis predictive of radiological progression?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3103808" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : 7S IgM in the sera of patients with arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1417131" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Clinical significance of rheumatoid factors in early rheumatoid arthritis: results of a follow up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2256736" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Disease activity and joint damage progression in early rheumatoid arthritis: relation to IgG, IgA, and IgM rheumatoid factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15696560" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Development and assessment of indicators of rheumatoid arthritis severity: results of a Delphi panel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7810933" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Extrahepatic immunologic manifestations in chronic hepatitis C and hepatitis C virus serotypes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7533120" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8138255" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Immunological disorders in C virus chronic active hepatitis: a prospective case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15742441" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Absence of cyclic citrullinated peptide antibody in nonarthritic patients with chronic hepatitis C infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9531323" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Clonal analysis of intrahepatic B cells from HCV-infected patients with and without mixed cryoglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5635288" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Changes in rheumatoid factor activity during the course of sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24489610" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Sarcoidois: is it only a mimicker of primary rheumatic disease? A single center experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18634144" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Osteoarticular involvement in a series of 100 patients with sarcoidosis referred to rheumatology departments.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21205465" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Superior specificity of anti-citrullinated peptide antibodies in patients with chronic lymphocytic leukemia and arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12375308" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Rheumatoid factors: what do they tell us?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5297562" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Serum anti-gamma-globulin and antinuclear factors in the aged.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14323543" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : STUDIES OF THE INCIDENCE AND SIGNIFICANCE OF ANTI-GAMMA GLOBULIN FACTORS IN THE AGING.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8000738" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Prevalence of selected autoantibodies in different elderly subpopulations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22956589" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Elevated rheumatoid factor and long term risk of rheumatoid arthritis: a prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1859489" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : The latex test revisited. Rheumatoid factor testing in 8,287 rheumatic disease patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12610800" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Prevalence of rheumatoid arthritis and hepatitis C in those age 60 and older in a US population based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22531929" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Chronic smoke exposure induces rheumatoid factor and anti-heat shock protein 70 autoantibodies in susceptible mice and humans with lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31427439" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Shared epitope defines distinct associations of cigarette smoking with levels of anticitrullinated protein antibody and rheumatoid factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10666174" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : A prospective study on the incidence of rheumatoid arthritis among people with persistent increase of rheumatoid factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14872479" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28337522" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Pre-symptomatic autoimmunity in rheumatoid arthritis: when does the disease start?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1456851" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : How useful is the rheumatoid factor? An analysis of sensitivity, specificity, and predictive value.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30658699" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : In rheumatoid arthritis, changes in autoantibody levels reflect intensity of immunosuppression, not subsequent treatment response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14969046" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Joint damage and disability in rheumatoid arthritis: an updated systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26961746" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Have radiographic progression rates in early rheumatoid arthritis changed? A systematic review and meta-analysis of long-term cohorts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22798565" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Rheumatoid factor determines structural progression of rheumatoid arthritis dependent and independent of disease activity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31410660" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Association of rheumatoid arthritis-related autoantibodies with pulmonary function test abnormalities in a rheumatoid arthritis registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26245322" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Rheumatoid Factor Is Associated With the Distribution of Hand Joint Destruction in Rheumatoid Arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7871331" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Serum IgM rheumatoid factor by enzyme-linked immunosorbent assay (ELISA) delineates a subset of patients with deforming joint disease in seronegative juvenile rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28217885" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Reductions in Radiographic Progression in Early Rheumatoid Arthritis Over Twenty-Five Years: Changing Contribution From Rheumatoid Factor in Two Multicenter UK Inception Cohorts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20498212" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19589891" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31826682" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Predictors of new bone erosion in rheumatoid arthritis patients receiving conventional synthetic disease-modifying antirheumatic drugs: Analysis of data from the DRIVE and DESIRABLE studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15509628" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Prospects for B-cell-targeted therapy in autoimmune disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28865493" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the RISING study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28668802" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Anticyclic Citrullinated Peptide Antibodies and Rheumatoid Factor as Risk Factors for 10-year Cardiovascular Morbidity in Patients with Rheumatoid Arthritis: A Large Inception Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : On the occurrence of a factor in human serum activating the specific agglutination of sheep blood corpuscles
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13372565" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : The latex fixation test. I. Application to the serologic diagnosis of rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4015199" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Routine quantification of rheumatoid factor by rate nephelometry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3761356" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : A rapid enzyme immunoassay for the detection of IgM rheumatoid factor--a comparison of "sero-negative" and "sero-positive" rheumatoid patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8087990" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Rheumatoid factor measured with the QM300 nephelometer: clinical sensitivity and specificity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9668731" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : A comparison of IgM rheumatoid factor by nephelometry and latex methods: clinical and laboratory significance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32277023" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : A Method To Prevent SARS-CoV-2 IgM False Positives in Gold Immunochromatography and Enzyme-Linked Immunosorbent Assays.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21305505" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Erroneous augmentation of multiplex assay measurements in patients with rheumatoid arthritis due to heterophilic binding by serum rheumatoid factor.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
